February 5th, 2018
Theresa Deisher, Ph.D., Founder of the Seattle-based biotech AVM Biotechnology, presented at the 4th Annual Biotech and Money / Medtech and Money World Congress, held in London, UK.
Biotech & Money is an invitation-only conference, and this year AVM was invited to share the exciting preliminary results on their lead molecule AVM0703. Non- clinical and preclinical data show AVM0703 has high potential to replace the toxic chemotherapy preconditioning used with CAR-T and other cancer cell therapies.
Dr. Deisher’s presentation stirred excitement among investors and industry experts as she introduced a new concept for cancer treatment: Cancer Cured or Made Chronic™. Dr. Deisher shared that “only ~50% of patients respond to the currently used chemotherapy preconditioning regimens for CAR-T cells, with huge relapse rates.” AVM0703 as a non-toxic CAR-T preconditioning agent could allow ~100% of these patients to be effectively treated, enabling cancer to either be cured or turned into a manageable, chronic disease.
Dr. Deisher also presented that AVM is seeking funds to bring AVM0703 into cancer immunotherapy and regenerative medicine clinical trials in 2018. The team has also been in active discussions with Key Opinion Leaders (KOLs) in oncology and musculoskeletal disease as potential principal investigators.
Headquartered in Seattle, WA, AVM is dedicated to the discovery, development, and commercialization of stem cell-enabling technologies for immuno-oncology, regenerative medicine and fully human biologics applications. With robust, global intellectual property (IP) and broad patent claims, AVM’s lead small molecule AVM0703 is ready to transform the worlds of immuno-oncology and regenerative cell therapies.